Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 5.21% |
| CYNOSURE INC | CYNO | 4.42% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
| BLOOMIN' | BLMN | 2.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Fred's Inc. ( FRED - Analyst Report ) reported first-quarter 2012 adjusted earnings of 28 cents, which exceeded the prior-year quarter earnings of 24 cents by 17%. However, earnings were in line with the Zacks Consensus Estimate. The earnings were at the higher end of management’s guidance range of 26 to 28 cents per share. Results were driven by strong sales in the pharmacy department and decent same-store sales.
Revenue and Margin Performance
Total sales increased 3% year over year to $500.5 million. Sales for the first quarter of fiscal 2012 surpassed the Zacks Consensus Estimate of $475 million. Fred’s comparable store sales slipped 0.4% during the quarter compared to a 1.0% rise in the year-ago quarter.
Gross profits grew 7% to $147.8 million, while gross margin expanded 100 basis points to 29.5% from the year-ago quarter. The improved margin was the result of promotional markdowns and higher rebates and allowances from vendors.
Selling, general and administrative expense margin, including depreciation and amortization, increased 70 basis points to 26.1% from 25.4% in the year-ago quarter, driven by higher depreciation and amortization, group medical expenses and legal and professional fees.
Operating income went up 13% to $17.1 million in the quarter, while margins expanded 30 basis points to 3.4% of sales.
Store Update
As part of the fiscal 2012 operating plan of opening 22 to 28 stores, Fred's opened 3 new stores and 4 express pharmacy stores during the quarter.
Fred's operates 707 discount general merchandise stores, which includes 21 franchised stores. Fred's stores are located in southeast U.S.
Other Financial Update
At the end of April 28, 2012, Fred’s cash and cash equivalents came down to $7.8 million from $57.1 million as of April 30, 2011.The company used cash for renovating its pharmacy stores and give it a new look. There were also number of new acquisitions in the pharmacy department which attributed to the significant decline in cash held by the company.
Guidance
Management expects tough retail conditions to continue across the markets in fiscal 2012. The company estimates that fiscal 2012 will witness the largest conversion of branded drugs to generic drugs. This will negatively affect comparable store sales. Comparable store sales are estimated to remain flat in the second quarter of 2012.
For the second quarter of 2012, Fred’s forecasts its total sales to increase 4% to 6%. The company expects earnings to grow between15% and 30% and remain within the range of 15 cents - 17 cents per share in the second quarter of 2012. Fred’s expects its 2012 earnings to be in the range of 98 cents to $1.04 per share.
Fred’s faces stiff competition from Dollar General Corporation ( DG - Snapshot Report ) , Walgreen Co. ( WAG - Analyst Report ) and Wal-Mart Stores Inc. ( WMT - Analyst Report ) . Currently, we have a long-term Neutral recommendation on Fred’s, which carries a Zacks #2 Rank (short-term Buy rating).
Read the full reports :
Analyst Report on WMT
Snapshot Report on DG
Analyst Report on WAG
Analyst Report on FRED